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Abstract For the microbiological diagnosis of a Clostridium
(C.) difficile infection (CDI), a two-test algorithm consisting of
a C. difficile glutamate dehydrogenase (GDH)-immunoassay
followed by a toxin-immunoassay in positive cases is widely
used. In this study, two chemiluminescent immunoassays
(CLIAs), one for GDH and the other for the toxins A and B,
havebeenevaluated systematicallyusing appropriate reference
methods. Three-hundred diarrhoeal stool specimens submitted
for CDI diagnosis were analysed by the LIAISON CLIAs
(DiaSorin). Toxigenic culture (TC) and cell cytotoxicity assay
(CCTA) were used as Bgold standard^ reference methods. In
addition, GDH and toxin A and B enzyme immunoassays
(EIAs), C. diff Chek-60 and toxin A/B II (TechLab), and the
Cepheid Xpert C. difficile polymerase chain reaction (PCR)
were performed. C. difficile was grown in 42 (14%), TC was
positive in 35 (11.7%) and CCTA in 25 (8.3%) cases. CLIAs
were more sensitive but less specific than the respective EIAs.
Usingcultureas reference, the sensitivityof theGDHCLIAwas
100%. In comparison to CCTA sensitivity, specificity, positive
predictive value and negative predictive value of the two-test
algorithm were 88, 99.3, 91.7 and 98.9% by CLIAs and 72,
99.6, 94.7 and 97.5% by EIAs. Discrepant results by CLIAs
were more frequent than that by EIAs (9% vs. 6.3%); in those
cases, PCR allowed for the accurate detection of toxigenic
strains.Due toperformance characteristics and testing comfort,
CLIAs in combinationwith PCR represent a favourable option
for the rapid laboratoryC. difficile diagnostics.
Introduction
Clostridium (C.) difficile infection (CDI) can cause a spectrum
o f d i s e a s e s f r om se l f - l im i t i n g d i a r r h o e a and
pseudomembranous colitis (PMC) to life-threatening condi-
tions such as toxic megacolon, perforation of the gut, and
sepsis. CDI is a major cause of diarrhoea in healthcare facili-
ties commonly affecting the most vulnerable patients after the
use of antibiotics, but was also shown to account for approx-
imately 2% of community acquired cases of diarrhoea [1, 2].
Toxigenic strains producing the toxins A and B are responsi-
ble for disease. During recent years, the incidence of hospital-
acquired C. difficile-associated diarrhoea has increased in
many countries, which may be due—at least in part—to the
epidemic spread of hypervirulent strains (e.g. ribotype 027)
[3, 4].
Accurate and rapid diagnosis of CDI is of crucial impor-
tance to ensure that patients receive appropriate treatment and
to control the spread of the infection. Clinical and laboratory
diagnoses are complicated by the fact that up to 25% of
hospitalised patients may be colonised with toxigenic
C. difficile strains without any symptoms [5]. Therefore, the
detection of a toxigenic strain in the faeces of a symptomatic
patient must not necessarily be the reason for the diarrhoea.
Thus, the presence of C. difficile toxins in faeces should cor-
relate better with CDI than culture of a toxigenic isolate (toxi-
genic culture, TC) [6].
The Bgold standard^ reference method for the detection of
C. difficile toxins (mainly toxin B) in faeces is considered to be
the cell cytotoxicity assay (CCTA) [7].However, this is a lengthy
assay with a time to result of 24 to 48 h. Alternatively, several
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commercially available enzyme immunoassays (EIAs) and
lateral-flow assays for diagnosis of toxins A and B have been
widely used. However, considerable differenceswere shown be-
tween those tests in their performance characteristics [8, 9].
Because of the low prevalence of CDI both in the healthcare
andespecially in thecommunitysetting thecommerciallyavail-
able tests exhibit high negative predictive values (NPVs), but
the positive predictive values (PPVs) are unacceptably low.
This applies not only to toxin EIAs but also to those detecting
the C. difficile surface-associated enzyme glutamate dehydro-
genase (GDH)andnucleic acidamplification tests (NAATs) for
the detection of either toxin A or B genes [8–12]. However,
GDH EIAs and NAATs show satisfactory sensitivities in com-
parison to culture and TC, respectively [10–14].
While none of these tests is appropriate to be used as a
stand-alone test, a two-step algorithm has been proposed by
the UK Department of Health guidance. This algorithm con-
sists of a GDH immunoassay or NAAT as screening test
followed by a sensitive toxin immunoassay for the re-
analysis of all positive samples. Due to considerably increased
pre-test probability this approach would yield excellent PPVs
and due to toxin detection it may also show a better correlation
with the disease [6, 15–19].
During recent years, twochemiluminescent immunoassays
(CLIAs), one for the detection of C. difficile GDH and the
other for the detection of toxinsA andB, became commercial-
ly available. The CLIA two-step algorithm allows for higher
testing comfort and flexibility as well as shorter time-to-result
in comparison to testing by EIAs. However, only few pub-
lished data exist with these tests [20, 21], and a systematic
evaluationof eachof themwith anappropriate referencemeth-
od was not provided in all cases. In the present study, the
performance of each of the CLIAs has been compared to an
appropriate Bgold standard^ reference method as well as a
widely used EIA, one for GDH and another for toxins A and
B. Also the performance characteristics of two-step algo-
rithms using the combination of either CLIAs or EIAs have
been analysed in comparison to both TC and CCTA.
Materials and methods
Samples Three hundred diarrhoeal stool specimens submitted
for CDI diagnosis have been included consecutively, if they
were less than 24 h old and of sufficient volume to allow
testing with all study-related assays in addition to routine test-
ing. The latter comprised an initial screening by a GDH EIA
(C. diff Chek-60; TechLab, Blacksburg, VA, USA). In case of
a positive result confirmatory PCR testing (Xpert C. difficile
assay; Cepheid, Sunnyvale, CA, USA) was conducted.
Specimens were given a study protocol number by the routine
staff and were, thereby anonymised, forwarded to the scien-
tific staff for further analysis by TC, CCTA, EIA for toxins A
and B and the two CLIAs, one for GDH and the other for
toxins A and B. The results of routine testing were communi-
cated to the clinical ward; those obtained by the study-related
tests were not disclosed, and therefore, did not impact the
patient’s management.
Cell cytotoxicity assay Faecal samples were diluted with an
equal volume of PBS, centrifuged and the supernatants were
filtered through a 0.2 μm filter. The assay was performed by
testing this sterile faecal filtrate in duplicates on a confluent
monolayer of Vero cells after preincubation of cells with either
PBS or C. difficile antitoxin. The final dilution of the stools
was 1:40. For positive and neutralisation controls the
Clostridium difficile toxin/antitoxin kit was used according
to the instructions of the manufacturer (TechLab). A positive
result was recorded if cell rounding was seen only in the un-
protected cells after 24 or 48 h of incubation in a 37 °C CO2-
incubator.
Culture All samples were cultured on Clostridium difficile
agar (bioMérieux, Marcy l’Etoile, France), following an alco-
hol shock treatment in 50:50 [vol/vol] absolute ethanol and
water. Cultures were incubated in an anaerobic atmosphere for
48 h. Suspicious colonies (gray-brown colonies with irregular
edges and a characteristic horse manure like odour) were fur-
ther analysed by matrix-assisted laser desorption ionisation -
time of flight mass spectrometry (MALDI-TOF MS) on a
Microflex instrument (Bruker Daltonics, Bremen, Germany).
Toxigenic cultureC. difficile isolates were inoculated to brain
heart infusion broth (BHI) (Oxoid, Basingstoke, United
Kingdom) and incubated for 48 h in anaerobic jars. Culture
supernatants were centrifuged before being added to Vero cell
monolayers. For each sample, two wells were prepared (with
and without C. difficile antitoxin).
Commercial tests C.diffChek-60and toxinA/B II, aGDHand
a toxin EIA respectively, were performed as described by the
manufacturer (TechLab) on a Tecan Minilyser instrument
(Tecan Group Ltd., Männedorf, Switzerland). The chemilumi-
nescent immunoassays LIAISON C. difficile GDH and
LIAISON C. difficile Toxins A&B (DiaSorin Inc, Stillwater,
MN,USA)were performed according to themanufacturers’ rec-
ommendations on a LIAISON Analyzer (DiaSorin). The
Cepheid Xpert C. difficile assay, which is a multiplex real-time
PCRassay,wasperformedontheCepheidGeneXpertDxsystem
following themanufacturers’ instructions.
Statistical analysis Sensitivity, specificity, PPVand NPVand
their 95% confidence intervals were calculated for each com-
mercial kit against the appropriate reference assay. No statis-
tical comparisons were performed between the toxin detection
assays and the GDH assays, as these measure different targets.
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Sensitivity and specificity were compared by applying exact
binomial tests on the off-diagonal counts of the McNemar
table, PPV and NPV by Fisher’s exact probability test. A p-
value below 0.05 was considered significant.
Results
Out of 300 samples, C. difficile could be grown in 42 (14%)
and TC was positive in 35 (11.7%) cases. Thus 83.3% of the
isolates were toxigenic. CCTA was positive in 25/300 cases
(8.3%), all of which were also positive by TC. Thus, CCTA
was positive in 71.4% (25/35) of TC positive cases.
In comparison to culture, the sensitivity, specificity, PPVand
NPVof theGDHtestingwere88.1, 99.6, 97.4 and98.1%byEIA
and 100, 96.5, 82.4 and 100% by CLIA (Table 1). In one case
culture, PCR and all toxin tests were negative, but both GDH
immunoassays were positive; thus, it cannot be excluded that a
non-toxigenic strain might have been present and the culture
result was potentially false negative. Statistical analysis revealed
that for the detection of GDH specificity and PPV were signifi-
cantly higher by EIA in comparison to CLIA (p = 0.013 and p =
0.039, respectively), whereas, on the other hand, the NPV by
CLIAwas significantly higher than that by EIA (p = 0.029).
Sensitivity, specificity, PPV and NPVof the toxin assays in
comparison to CCTAwere 72.0, 97.5, 72.0 and 97.5% by EIA
and 88.0, 94.9, 61.1 and 98.9% by CLIA (Table 2). Similarly to
the results for GDH testing, the toxin CLIA showed higher sen-
sitivity and lower specificity when compared to the toxin EIA.
However, the differences were not of statistical significance. In
one case CCTAwas most likely false negative because all other
tests, including both toxin immunoassays, were positive.
In comparison to TC the sensitivity, specificity, PPV and
NPV of the two-step algorithms were 54.3, 100, 100 and
94.3% by EIAs and 68.6, 100, 100 and 96.0% by CLIAs
(Table 3). In comparison to CCTA the respective values were
72, 99.6, 94.7 and 97.5% by EIAs and 88, 99.3, 91.7 and
98.9% by CLIAs (Table 4). Irrespective of the GDH test used
for the two-step comparisons to TC or CCTA, values in the χ2
test (Tables 3 and 4) were dependent solely on the toxin test.
Thus, numbers with the two EIAs were exactly the same as
those of the combination of the GDH CLIA with the toxin
EIA, and numbers with the two CLIAs were identical to those
of the combination of the GDH EIAwith the toxin CLIA.
In 19 cases (6.3%) the EIA GDH test was positive whereas
the toxin test was negative. In 7/19 cases TC, PCR and CCTA
were positive. Of the remaining 12 samples, seven were pos-
itive by TC and PCR and four were positive by culture; the
one which was positive solely by both GDH immunoassays
was considered false positive. As with CLIAs, in 27 cases
(9%) the GDH test was positive and the toxin test was nega-
tive. Of those, in three, TC, PCR and CCTAwere positive; in
eight, both TC and PCR were positive; in seven, culture was
positive; and in nine, the GDH test was considered false pos-
itive. Conversely, in six samples by EIAs and 12 by CLIAs we
observed a positive toxin result although the GDH test was
negative; all of these toxin test results were considered false
positive. In accordancewith the performance characteristics of
the two GDH and the two CLIA assays, the lowest number of
discrepant cases (n = 14) was observed by the combination of
the GDH EIAwith the toxin CLIA and the highest (n = 32) by
the combination of the GDH CLIAwith the toxin EIA.
PCR was performed in all GDH EIA positive cases but
also, in retrospect, in the two TC positive/GDH EIA negative
cases (Table 3) always yielding a positive result. Thus, the
sensitivity of PCR in comparison to TC was shown to be
100%. Performing PCR in discrepant cases either by EIAs
or CLIAs would improve the sensitivity of the respective
two-step algorithm towards TC in a highly significant manner
(p < 0.001; Table 3). Assay combinations including PCRwere
dependent solely on the GDH assay irrespective of the toxin
test used. Thus, in a three-step algorithm the combination of
the GDH CLIA with the toxin EIA would result in the same
outcome as that of the two CLIAs, and the combination of the
GDHEIAwith the toxin CLIAwould result in the same values
as those obtained by the two EIAs (Table 3).
Table 1 GDH assays compared to culture









GDH EIA Positive 37 1 88.1 (73.6–95.5) 99.6a (97.5–100) 97.4a (84,6–99.9) 98.1 (95.4–99.3)
Negative 5 257
GDH CLIA Positive 42 9 100 (89.6–100) 96.5 (93.3–98.3) 82.4 (68.6–91.1) 100b (98.1–100)
Negative 0 249
CLIA chemiluminescent immunoassays, EIA enzyme immunoassays, CI confidence interval, PPV positive predictive values, NPV negative predictive
values
a Statistically significantly higher than by CLIA
b Statistically significantly higher than by EIA
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Discussion
The use of CLIAs in C. difficile diagnosis represents an alter-
native to EIAs. The two EIAs used in the present study–C. diff
Chek-60 and toxin A/B II–have been evaluated in a number of
studies and are well-established for routine use [6, 8–11, 18,
19]. The comparison between the GDH assays using culture
as reference revealed a lower specificity and PPV but an ex-
cellent sensitivity and NPV of the CLIA, which was also
shown by others [20]. Thus, all culture-positive cases could
be detected by CLIA which suggests the appropriateness of
this test for the screening of CDI in stool samples.
With regard to the toxin assays, the higher sensitivity
of CLIA (88.0% vs. 72.0% when compared to the EIA)
may also disclose the suitability of this assay for toxin
detection in GDH antigen positive cases. However, an-
alogue to the GDH assays, the toxin CLIA was less
specific than the toxin EIA.
Thecombinationof theGDHwiththetoxinCLIA,bothshow-
ing higher sensitivities than the respective EIAs, resulted in a
considerably higher overall sensitivity than that shown by the
EIA testing algorithm. Thus, in comparison to CCTA, which
was recently shown to be the appropriate reference method for
the laboratory confirmation of CDI [6, 15], the difference in sen-
sitivity of the two-step algorithm between CLIAs and EIAs was
16%.Despite lower specificity values of bothCLIAs in compar-
isontotherespectiveEIAs, thespecificityof thecombinedtesting
in comparison to TC was 100%. There were only two cases
which were considered false positive by the CLIA two-step al-
gorithm in comparison to CCTA (Table 4). However, in one of
those cases all other tests including both toxin immunoassays
were positive which suggests a false negative CCTA result. In
the second case a toxigenic strain has been identified by TC and
PCR, but in contrast to the CCTA and toxin EIA only the toxin
CLIA yielded a positive result marginally above the threshold
value. Thus, even in that case a low toxin concentration—not
detected by the CCTA—may have been present.
Table 2 Toxin A&B assays compared to cell cytotoxicity assay









Toxin EIA Positive 18 7 72.0 (50.6–87.9) 97.5 (84.8–99.0) 72.0 (50.6–87.9) 97.5 (84.8–99.0)
Negative 7 268
Toxin CLIA Positive 22 14 88.0 (68.8–97.5) 94.9 (91.6–97.2) 61.1 (43.5–76.9) 98.9 (96.7–99.8)
Negative 3 261
CLIA chemiluminescent immunoassays, EIA enzyme immunoassays, CI confidence interval, PPV positive predictive values, NPV negative predictive
values
Table 3 GDH/toxin A&B algorithm by EIAs and CLIAs with and w/o PCR compared to toxigenic culture









EIAs Positivea 19 0 54.3 (36.7–71.2) 100 (98.6–100) 100 (82.4–100) 94.3 (90.9–96.7)
Negativeb 16 265
EIAs + PCRc Positived 33 0 94.5f (80.8–99.3) 100 (98.6–100) 100 (89.4–100) 99.3f (97.3–99.9)
Negative 2e 265
CLIAs Positivea 24 0 68.6 (50.7–83.2) 100 (98.6–100) 100 (85.8–100) 96.0 (93.0–98.0)
Negativeb 11 265
CLIAs + PCRc Positived 35 0 100f (90.0–100) 100 (98.6–100) 100 (90.0–100) 100f (98.6–100)
Negative 0 265
CLIA chemiluminescent immunoassays, EIA enzyme immunoassays, CI confidence interval, PCR polymerase chain reaction, PPV positive predictive
values, NPV negative predictive values
a Positive GDH assay confirmed by the toxin assay
b Either one of the assays or both assays negative
c PCR performed only in discrepant cases
d Either both immunoassays positive or positive PCR result in GDH positive and toxin negative cases
e False negative GDH assay
f Statistically significantly higher than by the respective two-step algorithm
Eur J Clin Microbiol Infect Dis
A considerable proportion of cases with positive GDH
but negative toxin CLIA results were attributable to a
false positive result by the GDH assay (9/27, 33.3%).
Quite contrary to CLIA testing, a similarly high propor-
tion of such discrepant cases found by EIAs was due to
false negative results by the toxin assay (7/19, 36.8%).
The proportion of cases of absence of toxins or presence
of non-toxigenic strains leading to positive GDH and
negative toxin assay results was similar between discrep-
ant cases found by CLIAs and EIAs (15/27, 55.6% vs.
11/19, 57.9%). Overall, the number of discrepant results
by CLIAs was higher than that by EIAs.
For further clarification of cases with positive GDH
and negative toxin test results it would be reasonable to
introduce a rapid NAAT as a third test. In this and pre-
vious studies the Cepheid Xpert C. difficile PCR showed
an excellent performance in comparison to TC. Some
authors even suggested using this PCR as a single labo-
ratory test for CDI diagnosis [12, 14, 22–24]. However,
apart from a considerable cost, the appropriateness of
NAATs for the laboratory confirmation of CDI has been
a controversial issue in recent literature [6, 15, 25].
Nonetheless, irrespective of the clinical relevance of a
positive molecular test result, it definitely identifies the
presence of a toxigenic strain, which may influence mea-
sures of infection control.
In the present study, PCR results, being available as
part of the routine analysis, were in total agreement
with TC. PCR was positive in the majority of cases
(14/19, 73.7%) of positive GDH and negative toxin test
results by EIAs, but only in 40.7% (11/27) of such
discrepant cases by CLIAs. However, irrespective of
the test system used, CLIAs or EIAs, the implementa-
tion of PCR as a third test should be seriously consid-
ered, because this would allow for the accurate detec-
tion of toxigenic strains among discrepant cases. In the
present study, the three-step algorithm would result in
significantly higher sensitivities both by CLIAs and
EIAs (100% vs. 68.6% and 94.5% vs. 54.3%, respec-
tively; p < 0.001) in comparison to TC.
Apart from diagnostic performance characteristics issues,
CLIAs showed to be more practical and convenient than the
EIAs for routine use. In contrast to Benedek et al. [20], we did
not experience any noteworthy technical drawbacks with the
system, upon optimization of the instrument settings of the
LIAISONAnalyzer. Samples can be processed individually up-
ontheirarrivalwithout theneedtocollectsamplesprior to testing.
The sample preparation time is less than 15min with only a few
minutes of actual hands-on time. If the GDH test is positive, the
toxinassay isperformedautomaticallywithout theneed forman-
ual intervention. The time-to-result is less than an hour for the
GDH test and takes a further 45minwhen a positiveGDH result
is followedby toxin testing. Incaseofadiscrepant result between
GDH and toxin assays, a rapid NAAT, e.g. the Cepheid Xpert
C. difficile PCR, can easily be performed subsequently allowing
for the generation of a same-day final report; due to the longer
time-to-result of more than 2.5 h for subsequent testing and the
lack of testing flexibility, this may not be as feasible by EIA
testing, particularly when tests are performedmanually.
The combination of the GDH EIA with the toxin CLIA
may also be taken into consideration, since it was associated
with the lowest number of discrepant results. Even if being
less practical than CLIA testing, it may lead to a lower overall
cost in case of a three-step algorithm including PCR.
In conclusion, CLIAs were more sensitive but less specific
than the respective EIAs. In particular, the GDH CLIA with
100% sensitivity in comparison to culture clearly fulfils the
requirements of a screening test in terms of excellent sensitiv-
ity. Moreover, the sensitivity of toxin detection in GDH pos-
itive cases in comparison to CCTA was considerably higher
when using CLIAs instead of EIAs. However, the number of
cases with positive GDH and negative toxin test results was
higher by CLIAs than that by EIAs, suggesting a more urgent
need of a third test, e.g. a rapid NAAT, for further clarification.
Finally, due to their performance characteristics as well as the
shorter hands-on time, shorter time-to-result and higher
Table 4 GDH/toxin A&B algorithm by EIAs and CLIAs compared to cell cytotoxicity assay









EIAs Positivea 18 1 72.0 (50.4–87.1) 99.6 (97.7–100) 94.7 (71.9–99.7) 97.5 (94.7–98.9)
Negativeb 7c 274
CLIAs Positivea 22 2 88.0 (67.7–96.8) 99.3 (97.1–99.9) 91.7 (71.5–98.5) 98.9 (96.6–99.7)
Negativeb 3c 273
CLIA chemiluminescent immunoassays, EIA enzyme immunoassays, CI confidence interval, PPV positive predictive values, NPV negative predictive
values
a Positive GDH assay confirmed by the toxin assay
b Either one of the assays or both assays negative
c True positive GDH assay and negative toxin assay
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flexibility by testing in comparison to EIAs, CLIAs in combi-
nation with a NAATmay currently represent the most suitable
option for rapid laboratory C. difficile diagnostics.
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